Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16658764 | 0.98 | HDAC1 (0.72) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL16658766 | 0.98 | HDAC1 (0.72) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL16658763 | 0.98 | HDAC1 (0.72) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL5990328 | 0.98 | HDAC1 (0.72) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL8009605 | 0.98 | HDAC1 (0.72) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL16658762 | 0.98 | HDAC1 (0.72) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL14419004 | 0.95 | HDAC1 (0.72) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL622139 | 0.94 | HDAC1 (0.70) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL14643880 | 0.90 | HDAC2 (0.74) | HDAC1HDAC2ALOX5HDAC3HDAC8 | |
| SCHEMBL20373704 | 0.89 | HDAC1 (0.65) | HDAC1HDAC2ALOX5HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-104892542-B | The 2 carbonyl thiazoles and 2 carbonyl oxazoles of anti-inflammatory | 埃维克辛公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-103772312-B | The 2-carbonyl thiazole of anti-inflammatory and 2-carbonyl oxazole | 埃维克辛公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-104892542-A | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS | 2015-09-09 | — | — | CN | disclosed |
| CN-102647984-B | Anti-inflammatory 2-carbonylthiazoles and 2-carbonyloxazoles | AVEXXIN AS | 2015-03-25 | — | — | CN | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
| EP-1441726-A1 | DERIVATIVES OF PHENOXY-N-'4-(ISOTHIAZOLIDIN-1,1-DIOXID-2YL)PHENY!-VALERIAN- ACID AMIDE AND OTHER COMPOUNDS AS INHIBITORS OF THE COAGULATION FACTOR XA IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMORS | Merck Patent GmbH (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039543-A1 | DERIVATIVES OF PHENOXY-N-'4-(ISOTHIAZOLIDIN-1,1-DIOXID-2YL)PHENY!-VALERIAN- ACID AMIDE AND OTHER COMPOUNDS AS INHIBITORS OF THE COAGULATION FACTOR XA IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMORS | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | HDAC1 993/4885HDAC2 514/4885ALOX5 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.